ChiCTR2300070071: Phase I clinical study to evaluate the safety, tolerability and pharmacokinetic profile of single and multiple doses of peramivir inhalation solution in healthy Chinese adult subjects |
|
|
| Not yet recruiting | 1 | 60 | | Peramivir inhalation solution (initially 20 mg) administered by both oral or face mask nebulized inhalation ;Two cycles of cross-administration of paramivir inhalation solution or paramivir sodium chloride injection ;3:1 randomized, 9 received peramivir inhalation solution and 3 received placebo administration ;3:1 randomized, 9 received peramivir inhalation solution and 3 received placebo administration | Center for Clinical Pharmacology, the Third Xiangya Hospital of Central South University; The third Xiangya Hospital of Central South University, Guangzhou Nanxin Pharmaceutical Co., Ltd. | Influenza | | | | |
